Enterobacterales are important pathogens responsible for healthcare-associated infections and can cause various severe infectious diseases. Since their first report, extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) have become widely prevalent worldwide. These strains often exhibit multidrug resistance, significantly increase the risk of treatment failure and patient mortality. In China, the prevention and control of ESBL-E faces numerous challenges, including high prevalence rates, significant regional distribution disparities, uneven laboratory detection capabilities, and variations in antimicrobial stewardship and prescribing practices. To address these issues, Professors Zhuo Chao, Xu Yingchun and Yu Yunsong initiated the development of the Expert consensus on clinical management strategies for infections caused by extended-spectrum β-lactamase-producing Ente-robacterales (2025), in collaboration with multidisciplinary experts. This consensus systematically reviews the global and domestic epidemiological characteristics of ESBL-E, clinical laboratory detection techniques, treatment principles and key therapeutic agents, as well as infection prevention and control measures. Furthermore, it elaborates on the microbiological features and stratified treatment strategies for infections of different sources (including bloodstream, intracranial, respiratory system, thoracic mediastinal, intra-abdominal, and urinary tract infections) and special populations (such as neutropenic patients with fever, emergency patients, and pediatric patients). The consensus aims to enhance the detection capacity of clinical laboratories for ESBL-E, standardize diagnosis and treatment strategies in healthcare settings, and provide scientific guidance to curb the spread of ESBL-E in China, thereby reducing associated morbidity and mortality.